[1]曹婷婷,陈桂芬,范玉香,等.视网膜分支静脉阻塞合并黄斑水肿不同治疗方法的疗效观察[J].眼科新进展,2014,34(8):772-775.[doi:10.13389/j.cnki.rao.2014.0213]
 CAO Ting-Ting,CHEN Gui-Fen,FAN Yu-Xiang,et al.Clinical observation in different treatment methods of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2014,34(8):772-775.[doi:10.13389/j.cnki.rao.2014.0213]
点击复制

视网膜分支静脉阻塞合并黄斑水肿不同治疗方法的疗效观察
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
34卷
期数:
2014年8期
页码:
772-775
栏目:
应用研究
出版日期:
2014-08-05

文章信息/Info

Title:
Clinical observation in different treatment methods of branch retinal vein occlusion
作者:
曹婷婷陈桂芬范玉香王志学李朝霞
河北省沧州市,沧州市中心医院眼一科
Author(s):
CAO Ting-TingCHEN Gui-FenFAN Yu-XiangWANG Zhi-XueLi Zhao-Xia
关键词:
视网膜分支静脉阻塞黄斑水肿曲安奈德光凝时机
Keywords:
branch retinal vein occlusion macular edema triamcinolone acetonide photocoagulation opportunity
DOI:
10.13389/j.cnki.rao.2014.0213
文献标志码:
A
摘要:
目的 通过对视网膜分支静脉阻塞(branchretinalveinocclusion,BRVO)在不同时期进行光凝及光凝联合玻璃体内注射曲安奈德治疗进行比较,探索治疗BRVO合并黄斑水肿更为有效的方法。方法 75例BRVO患者纳入研究,均为单眼。将所有患者分为5组,A组14例、病程为3~6个月,B组16例、病程<3个月,以上两组入选后即行黄斑区局部格栅样光凝及颞上象限局部光凝治疗,C、D、E组均为入选后即行玻璃体内注射曲安奈德4mg,注射后光凝时间分别为2周、4周、6周,每组15例。对比观察5组治疗前后最佳矫正视力(bestcorrectedvisualacuity,BCVA)、光学相干断层扫描(opticalcoherencetomography, OCT)、多焦视网膜电图(multifocalelectroretinogram,mfERG)结果。结果 BCVA:5组中以C组BCVA改善最为显著,优于A、B、D、E组(均为P<0.05)。OCT结果:C组最终黄斑中心凹厚度与A、B、D、E组相比,差异均有统计学意义(均为P<0.05),D、E组均明显低于A、B组(均为P<0.05)。mfERG结果:C、D、E各组黄斑区(即1、2环)P1、N1波振幅密度分别与A、B组比较明显增加,差异均有统计学意义(均为P<0.05)。结论 玻璃体内注射曲安奈德联合光凝治疗BRVO效果优于单纯激光治疗,玻璃体内注射曲安奈德2周后行激光光凝治疗效果最佳。
Abstract:
Objective To explore the more effective method for branch retinal vein occlusion ( BRVO)with macular edema by analyzing the laser coagulation and intravitreal injection of triamcinolone acetonide combined with laser coagulation in different periods. Methods Seven-five BRVO patients ( 75 eyes) included in this research. and divided into five groups , 14 cases in group A with duration of 3 - 6 months . 16 cases in group B with duration less than 3 months , group A and B were treated with macular and superior-temple local area laser at once. The patients in group C , D and E received the intravitreal injection of 4 mg triamcinolone acetorude at once, then performed the photocoagulation for 2 weeks ,4 weeks and 6 weeks . 15 cases rn each group. The preoperative and postoperative best correct visual acuity ( BCVA) , optical coherence tomography ( OCT) and multifocal electroretinogram ( mfERG) were compared among five groups. Results BCVA in group C improved the most sigruficant , better than group A, B , D and E ( all P < 0. 05 ) . There were statistical differences in macular foveal thickness between group C and group A,B.D and E ( all P <0. 05) , and group D and E were lower than group A and B ( all P < 0. 05 ) . The amplitude density of Pl ,NI wave at macular area ( ring I ,2)in group C,D,E were higher than those in group A and B.there were statistical differences ( all P < 0. 05 ) . Conclusion The intravitreal injection of triamcinolone acetonide combined with laser coagulation has better effects than single laser coagulation,and laser coagulation at 2 weeks after triamcinolone acetonide injection can achieve the best effects.

相似文献/References:

[1]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[2]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[3]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[4]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[5]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[6]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[7]陈素芳 曾莉 邵毅. 非诺贝特在糖尿病视网膜病变中的应用进展[J].眼科新进展,2014,34(3):283.
[8]肖昂,周琼.Aflibercept治疗湿性AMD和黄斑水肿的相关研究现状[J].眼科新进展,2014,34(6):598.[doi:10.13389/j.cnki.rao.2014.0165]
[9]魏光杰,何佃菊.532nm绿激光格栅样光凝联合球内注药治疗糖尿病视网膜病变黄斑水肿[J].眼科新进展,2014,34(8):779.[doi:10.13389/j.cnki.rao.2014.0215]
 WEI Guang-Jie,HE Dian-Ju.532 run green grid laser photocoagulation combined with intravitreal Avastin injection for diabetic retinopathy macular edema[J].Recent Advances in Ophthalmology,2014,34(8):779.[doi:10.13389/j.cnki.rao.2014.0215]
[10]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗(Ranibizumab)治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[11]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[12]傅维娜,陈梅珠,王云鹏. Lucentis联合视网膜光凝治疗视网膜分支静脉阻塞继发黄斑水肿[J].眼科新进展,2015,35(3):270.[doi:10.13389/j.cnki.rao.2015.0072]
 FU Wei-Na,CHEN Mei-Zhu,WANG Yun-Peng. Intravitreal injection with lucentis combined with local retinal photocoagulation for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(8):270.[doi:10.13389/j.cnki.rao.2015.0072]
[13]李仕永,高瑞莹,陈晖.雷珠单抗联合氩激光视网膜光凝治疗不同时期的视网膜分支静脉阻塞所致黄斑水肿的疗效[J].眼科新进展,2016,36(12):1161.[doi:10.13389/j.cnki.rao.2016.0309]
 LI Shi-Yong,GAO Rui-Ying,CHEN Hui.Effects of ranibizumab ( Lucentis) intravitreal injection combined with retinal argon laser photocoagulation on macular edema secondary to different period of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(8):1161.[doi:10.13389/j.cnki.rao.2016.0309]
[14]刘广峰,洪婷婷,苗森,等.玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究[J].眼科新进展,2017,37(7):658.[doi:10.13389/j.cnki.rao.2017.0167]
 LIU Guang-Feng,HONG Ting-Ting,MIAO Sen,et al.Comparison of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(8):658.[doi:10.13389/j.cnki.rao.2017.0167]
[15]石蕊,肖云芳,王峰,等.糖尿病合并视网膜分支静脉阻塞患者继发黄斑水肿后视力损伤程度及危险因素[J].眼科新进展,2017,37(12):1139.[doi:10.13389/j.cnki.rao.2017.0287]
 SHI Rui,XIAO Yun-Fang,WANG Feng,et al.Vision impairment following macular edema secondary to diabetes combined with branch retinal vein occlusion and its potential risk factors[J].Recent Advances in Ophthalmology,2017,37(8):1139.[doi:10.13389/j.cnki.rao.2017.0287]
[16]江慧娟,庞东渤.视网膜光凝联合玻璃体内注射雷珠单抗治疗缺血型视网膜分支静脉阻塞(BRVO)致黄斑水肿的疗效[J].眼科新进展,2018,38(4):348.[doi:10.13389/j.cnki.rao.2018.0081]
 JIANG Hui-Juan,PANG Dong-Bo.Efficacy of intravitreal ranibizumab combined with laser photocoagulation for the treatment of macular edema induced by ischemic branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(8):348.[doi:10.13389/j.cnki.rao.2018.0081]
[17]赵芃芃,秦梅.视网膜分支静脉阻塞治疗研究现状[J].眼科新进展,2018,38(5):485.[doi:10.13389/j.cnki.rao.2018.0114]
 ZHAO Peng-Peng,QIN Mei.Treatment research status of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(8):485.[doi:10.13389/j.cnki.rao.2018.0114]
[18]林国乔,郑德志,陈伟奇.康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的临床研究[J].眼科新进展,2018,38(11):1055.[doi:10.13389/j.cnki.rao.2018.0248]
 LIN Guo-Qiao,ZHENG De-Zhi,CHEN Wei-Qi.Clinical outcomes of intravitreal Conbercept injection for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(8):1055.[doi:10.13389/j.cnki.rao.2018.0248]
[19]杨大勇,李琳.雷珠单抗联合激光光凝术治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿疗效观察[J].眼科新进展,2019,39(4):369.[doi:10.13389/j.cnki.rao.2019.0084]
 YANG Da-Yong,LI Lin.Ranibizumab combined with laser photocoagulation in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(8):369.[doi:10.13389/j.cnki.rao.2019.0084]
[20]尹小芳,叶祖科,汤秀容,等.玻璃体内注射雷珠单抗后视网膜分支静脉阻塞性黄斑水肿复发的危险因素分析[J].眼科新进展,2020,40(1):046.[doi:10.13389/j.cnki.rao.2020.0011]
 YIN Xiaofang,YE Zuke,TANG Xiurong,et al.Risk factors for recurrence of macular edema associated with branch retinal vein occlusions after intravitreal injection of Ranibizumab treatment[J].Recent Advances in Ophthalmology,2020,40(8):046.[doi:10.13389/j.cnki.rao.2020.0011]

更新日期/Last Update: 2014-07-30